Description
Dacomitinib
Each film-coated tablet contains: Dacomitinib. … 15mg. • INDICATION: LuciDac is a kinase inhibitor indicated for the first -line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations. • DOSAGE AND USE: Recommended Dosage: 45 mg orally once daily with or without food. • STORAGE: In a dry place and store at 20°C to 25°C. • MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos • WARNING: Keep medicine out of reach of Children. Do not administer LuciDac during Pregnancy and Lactation.
Dacomitinib
Each film-coated tablet contains: Dacomitinib … 45mg.
INDICATION
LuciDac is a kinase inhibitor indicated for the first -line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
DOSAGE AND USE
Recommended Dosage: 45 mg orally once daily with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos.
WARNING
Keep medicine out of reach of Children. Do not administer LuciDac during Pregnancy and Lactation.
Reviews
There are no reviews yet.